You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

354 Results
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Lenvima®
Sep 2023
Drug
Other Name(s): Darzalex®
Jan 2023
Drug
Other Name(s): Somatuline® Autogel®
Jun 2024
Drug
Other Name(s): Onivyde® (Baxalta Canada)
Sep 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Jun 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
May 2024
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Aug 2025

Pages